Related Experiment Video

Updated: Sep 13, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance

Linjuan Wang1, Yue Qiu2, Xiang Huang1

  • 1Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, 361000, China.

Lipids in Health and Disease
|July 31, 2025
PubMed

Insights

Cholesterol may drive resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Understanding this link could lead to new treatments overcoming EGFR-TKI resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improve survival in EGFR-mutated non-small cell lung cancer (NSCLC).
  • Acquired resistance to EGFR-TKIs limits long-term therapeutic benefits.
  • Intracellular cholesterol is implicated in cancer progression and may influence treatment resistance.

Purpose of the Study:

  • To review the association between cholesterol and EGFR-TKI resistance in NSCLC.
  • To explore potential therapeutic strategies targeting cholesterol metabolism to overcome resistance.

Main Methods:

  • Literature review of studies investigating cholesterol's role in cancer.
  • Analysis of research on EGFR-TKI resistance mechanisms in NSCLC.
  • Synthesis of findings linking cholesterol levels to treatment outcomes.

Main Results:

  • Emerging evidence suggests elevated cholesterol levels correlate with resistance to EGFR-TKIs in NSCLC.
  • Cholesterol may impact signaling pathways crucial for EGFR-TKI efficacy.
  • Specific mechanisms of cholesterol-mediated resistance are being elucidated.

Conclusions:

  • Cholesterol represents a potential therapeutic target for overcoming EGFR-TKI resistance in NSCLC.
  • Further research is needed to validate cholesterol-modulating strategies for clinical application.
  • Targeting cholesterol could enhance the effectiveness of EGFR-TKIs in advanced NSCLC.
Keywords:
CholesterolCholesterol homeostasisEGFR-TKI resistanceNSCLC

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

6.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
689
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K